摸不到肿块≠没得淋巴瘤！专家：别让滤泡性淋巴瘤拖成大病

Core Insights - Lymphoma, particularly follicular lymphoma (FL), is a significant health threat and its incidence is rising in China due to aging population and improved diagnostic capabilities [1][2] - Recent advancements in treatment options for FL have been highlighted at the 67th American Society of Hematology (ASH) annual meeting, showcasing new therapies such as monoclonal antibodies, CD3/CD20 bispecific antibodies, CAR-T therapy, and BTK inhibitors [1][8] Group 1: Treatment Advances - New therapies have improved treatment outcomes and provided patients with alternatives, especially for those who fear chemotherapy side effects [2][8] - The introduction of bispecific antibodies represents an innovative direction in FL treatment, enhancing patient quality of life and offering new avenues for refractory cases [2][8] - The shift towards non-chemotherapy strategies is gaining traction, focusing on targeted and immunological mechanisms to improve patient outcomes while minimizing toxicity [6][8] Group 2: Disease Characteristics and Challenges - Follicular lymphoma accounts for approximately 8.1% to 23.5% of non-Hodgkin lymphoma cases in China, with a rising trend in incidence [2][3] - Despite initial positive responses to treatment, recurrence remains a major challenge, with up to 20% of patients experiencing disease progression within two years [3][5] - The long disease course and the potential for transformation into aggressive lymphoma highlight the need for ongoing vigilance and innovative treatment approaches [3][5] Group 3: Clinical Management - Early symptoms of follicular lymphoma are often non-specific, leading to late diagnoses; patients may present with painless lymphadenopathy or systemic symptoms [4][5] - Treatment decisions should be based on the specific clinical scenario, with careful assessment of disease stage and symptoms to determine the need for intervention [6][7] - The treatment goal has evolved from mere disease control to achieving deep remission and long-term survival, with functional cure becoming a realistic objective due to new therapies [7][8]